Early Phase 1 N=12 Oxytocin Effects on Cardiac Electrophysiology
Cardiac Arrhythmia
Primary: Change in Electrophysiology Measure of AH Interval — 12.7; -1.5 milliseconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3 Indocyanine Green (ICG) and SPY Imaging for Assessment of Burn Healing
Burns
Primary: Perfusion of Burned Area — 200; 100; 205; 180 % perfusion compared to normal skin
N/A N=36 Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma
Normal-Tension Glaucoma
Primary: Arterial Pressure — 100.9; 95.5 mmHg
Phase 3 N=21 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Non-functioning Pituitary Adenomas · Prolactinomas
Primary: Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma — 3.8; 29.35 cmˆ3 — p=<0.05
N/A N=39 Effect of Increased Light Exposure on Fatigue in Breast Cancer
Breast Cancer
Primary: Fatigue — 15.25; 21.6 units on a scale
Phase 2 N=158 A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
Relapsing Remitting Multiple Sclerosis
Primary: Confirmed Relapse, Annualized Relapse Rate — 0.25; 0.37 relapses per year — p=0.077
Phase 2 N=288 Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer · Efficacy
Primary: Progression Free Survival (PFS) — 168; 140 day
Phase 4 N=116 Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire — 41.22; 31.70 score on a scale
N/A N=4,680 PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response by Genotype in Modified All Treated Population — 40.6; 60.4; 55.0; 36.0 Percentage of participants
N/A N=26 Sensory Effects of Rapidly-Changing Magnetic Fields
Sensory Disorders
Primary: Degree of Discomfort Under Applied Pulsed Magnetic Fields — 0 percentage of subjects with discomfort
N/A N=12 Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions
Thrombocythemia · Myeloproliferative Disease · Thrombocytosis
Primary: Percent Change in Platelet (PLT) Count in Patient Blood Following Apheresis Procedure — -58.2 % change in PLT count in subject blood
Phase 3 N=1,216 Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Patients With Serious Adverse Events — 55; 55; 50 Participants
N/A N=11 Evaluation of Intra-articular Injection of Autologous Protein Solution ("APS(TM)") for the Treatment of Osteoarthritis (OA)
Gonarthrosis · Knee Osteoarthritis · Osteoarthritis
Primary: Number of Adverse Events — 22 Adverse Events (AEs)
Phase 2 N=32 Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
Invasive Breast Cancer
Primary: Rate of Achievement of Pathological Complete Response (pCR) — 9 pathology specimens from participants
Phase 2 N=72 Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
Graft Versus Host Disease · Systemic Scleroderma
Primary: Significant Clinical Response — 9; 10 participants